SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Evercore ISI Maintains C4 Therapeutics’ $12 Price Target and Outperform Rating

Valid market news retained in the public archive without immediate LiveCast distribution.

CCCC

Related stories